{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-008794","form_type":"8-K","ticker":"ACTU","cik":"0001652935","company_name":"ACTUATE THERAPEUTICS, INC.","filed_at":"2024-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.116492+00:00","generated_at":"2026-05-29T02:25:35.668561+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Actuate Therapeutics: elraglusib Phase 2 meets primary endpoint; 1-year survival 43.6% vs 22.5% in mPDAC","bullets":["1-year survival rate 43.6% in elraglusib+GnP arm vs 22.5% in GnP alone (p=0.002); median OS 9.3 vs 7.2 months (HR=0.63, p=0.016).","37% reduction in risk of death; ORR 27.7% vs 20.5%; multiple patients with complete/partial responses and 100% target lesion reduction.","Favorable safety profile; TEAEs and SAEs similar between arms; 2 patients with previously inoperable lesions successful resected.","Trial fully enrolled (286 patients); topline data expected 1H 2025; planned FDA engagement for Phase 3 registration trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-008794","json":"https://secwatch.observer/filing/0001683168-24-008794.json","markdown":"https://secwatch.observer/filing/0001683168-24-008794.md","text":"https://secwatch.observer/filing/0001683168-24-008794.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652935/000168316824008794/0001683168-24-008794-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652935/000168316824008794/actuate_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:25:35.668561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}